UK St. Claire Offers PAXLOVID™ as Treatment Option for COVID-19

If you test positive for COVID-19 and are at high risk for complications, you may benefit from PAXLOVID™. PAXLOVID is now available at UK St. Claire (SCH) for eligible patients.

PAXLOVID is an oral medication used for the treatment of patients with mild to moderate COVID-19 that are at least 12 years or older and are at increased risk for progressing to severe disease and/or requiring hospitalization. PAXLOVID is not available for patients who require oxygen to treat their COVID-19 symptoms.

If any of the criteria below apply to you, you may be eligible for PAXLOVID.

• Older age (Ex: age ≥65 years of age)
• Obesity or being overweight
• Pregnancy
• Chronic kidney disease
• Diabetes
• Immunosuppressive disease or immunosuppressive treatment (like daily prednisone)
• Heart disease (including congenital heart disease)
• Hypertension
• Lung diseases (Ex: chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, or pulmonary hypertension)
• Sickle cell disease
• Neurodevelopmental problems (Ex: cerebral palsy) or other conditions that confer medical complexity (Ex: genetic or metabolic syndromes, or severe congenital anomalies)
• Having a medical-related technological dependence (Ex: tracheostomy, gastrostomy, or positive pressure ventilation not related to COVID-19)

The FDA has authorized PAXLOVID for emergency use. SCH provides PAXLOVID to eligible patients at no cost.

To find out if PAXLOVID is right for you, complete an online questionnaire at www.st-claire.org/COVIDTreatment, or call 606.783.7539. Patients will be referred for a virtual visit with pharmacy to complete the eligibility process. If a patient is not eligible for PAXLOVID, monoclonal antibody treatment may be a treatment option.